Aligos Therapeutics Inc ALGS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/30/22 EDT
1.15quote price arrow up+0.05 (+4.55%)
Volume
1,812
Close
1.10quote price arrow up+0.04 (+3.77%)
Volume
32,845
52 week range
0.98 - 17.97
Loading...
  • Open1.10
  • Day High1.12
  • Day Low1.07
  • Prev Close1.06
  • 52 Week High17.97
  • 52 Week High Date11/08/21
  • 52 Week Low0.98
  • 52 Week Low Date09/26/22

Key Stats

  • Market Cap47.09M
  • Shares Out42.81M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-90.73

KEY STATS

  • Open1.10
  • Day High1.12
  • Day Low1.07
  • Prev Close1.06
  • 52 Week High17.97
  • 52 Week High Date11/08/21
  • 52 Week Low0.98
  • 52 Week Low Date09/26/22
  • Market Cap47.09M
  • Shares Out42.81M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-90.73

RATIOS/PROFITABILITY

  • EPS (TTM)-2.98
  • P/E (TTM)-0.37
  • Fwd P/E (NTM)-0.54
  • EBITDA (TTM)-124.179M
  • ROE (TTM)-82.64%
  • Revenue (TTM)8.17M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,547.22%
  • Debt To Equity (MRQ)0.34%

EVENTS

  • Earnings Date11/02/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aligos Therapeutics Inc

 

Profile

MORE
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD), and cirrhosis, end-stage liver...
Lawrence Blatt Ph.D.
Chairman of the Board, Chief Executive Officer
Leonid Beigelman Ph.D.
President, Director
Lesley Calhoun
Chief Financial Officer, Executive Vice President
Matthew Mcclure M.D.
Executive Vice President, Chief Medical Officer
Julian Symons Ph.D.
Executive Vice President, Chief Scientific Officer
Address
One Corporate Dr., 2nd Floor, 2nd Floor
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
ISR
IsoRay Inc
0.2299+0.01+4.55%
ONCT
Oncternal Therapeutics Inc
0.8916+0.0178+2.04%
NHWK
NightHawk Biosciences Inc
1.75-0.06-3.31%
DYAI
Dyadic International Inc
1.91+0.02+1.06%
AGLE
Aeglea Bio Therapeutics Inc
0.526+0.0361+7.37%